Heart-Lung Machine: Impact of the Priming Solution on Acid-Base Balance, Electrolytes and Outcome on Patients Undergoing Cardiac Surgery

NCT ID: NCT07267546

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most cardiac surgery procedures requires the use of heart-lung machine. The heart-lung machine circuit needs to be filled with a fluid before connecting it to the patients circulation. This is called priming and is accomplished by filling the circuit with a solution used for fluid replacement. The circuit in our institution requires 1100 mL to be filled.

The body has several mechanisms with the purpose to maintain its state of balance. When a large amount of clear solution suddenly enters the blood stream this balance can be altered. The goal of this clinical trial is to investigate different priming solutions in the heart-lung machine circuit. The main questions it aims to answer are:

How do different priming solutions alter the acid-base balance, osmolality and electrolytes which reflects the body's water balance for patients undergoing cardiac surgery with the use of heart-lung machine?

There will be 4 different groups:

1. Ringer-Acetate, 1100 mL / no addition
2. Ringer-Acetate, 1100 mL + 80 mmol sodium chloride (NaCl)
3. Ringer-Acetate, 1100 mL + 160 mmol NaCl
4. Plasmalyte, 1100 mL / no addition Blood samples will be taken before, during and after surgery, post operative day 1 and 4 to analyze acid-base balance, electrolytes, and plasma osmolality. Urine output and hydration status will also be collected until post operative day 1. After 3 months, a blood sample will be taken for analysis of electrolytes and kidney function.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiopulmonary bypass (CBP) with a heart-lung machine is mandatory for a vast majority of cardiac surgeries. Briefly the disposables in a CPB circuit consists of a reservoir, an oxygenator and tubings.

The role of CPB can be summarized as follows:

1. Empty the heart. Drain out the blood (achieved via venous cannulas).
2. Oxygenate the blood and remove carbon dioxide. Thus, the lungs are not participating during CPB.
3. Maintain homeostasis and adjust chemical and electrolyte blood composition.
4. Maintain or adjust the body's temperature via a heat exchanger, which is a part of the heart-lung machine.
5. Return oxygenated blood to the patient via arterial cannula.

Heart-lung machine provides even the following:

1. Salvage blood loss during surgery via cardiotomy suckers and return it to the patient.
2. Prevent distention of the heart during surgery via cardiac vents.
3. Deliver cardioplegia which stops the heart, providing myocardial protection and condition to perform cardiac surgery.
4. Additional treatments, such as hemofiltration and removing av cytokines.

Before connecting the CPB circuit to the patient's circulation it needs to be deaired. This is achieved by priming, i.e. filling the circuit with a liquid solution. The 2024 EACTS (European Association for Cardio-Thoracic Surgery)/EACTA (European Association of Cardiothoracic Anaesthesiology)/EBCP (European Board of Cardiovascular Perfusin) Guidelines on CPB in adult cardiac surgery point out that despite a wealth of studies, no consensus has been reached on the optimal composition of the priming solution. According to recent surveys, balanced crystalloids are the preferred priming solution, but there are no recommendations of the composition in the solution. The standard prime solution at our institution consists of Ringer Acetate which is a common crystalloid fluid in Sweden used intravenously for fluid and volume loss. Due to its composition, i.e. lower pH and sodium and higher chloride concentrations than the human blood, it is sometimes necessary to add electrolytes and other components to the circuit either in advance or after initiation of CPB. Previous studies have investigated various prime compositions and plasma osmolality. The crystalloid priming fluid used in these studies contained mannitol, which has a high osmolality. A former study from our group showed a significant decrease in blood sodium with a mannitol-containing prime, but no effects on plasma osmolality. Highly osmolar priming solution has further been studied, also containing mannitol, and found a steep rise in plasma osmolality. These studies used priming fluids with an addition of 80 mmol NaCl and 160 mmol NaCl, respectively. Plasmalyte is a newer crystalloid solution with a composition of sodium and chloride more similar to human plasma which could be of advantage. Plasmalyte is used for CPB priming in some cardiac centers. Studies on Plasmalyte as a priming solution have shown less metabolic acidosis compared to Ringer Lactate. However, it has not been used in our institution for this purpose and there are no studies comparing Plasmalyte with Ringer Acetate. The literature search has further not found any studies investigating non-mannitol CPB priming solutions with differing additions of NaCl. There is a need to fill this knowledge gap to proceed in developing of the optimal priming solution, tailored to variouse preexisting diseases or conditions.

Scientific questions The overall aim of the project is to investigate if clinical outcome after cardiac surgery can be improved by optimizing the priming solution.

The sub-projects will answer the questions:

* Do the different priming solutions: Ringer Acetate alone, Ringer Acetate with added NaCl and Plasmalyte alone affect the acid-base balance and composition of electrolytes in the blood?
* Do the different priming solutions affect the need to correct the acid-base balance during the heart-lung machine period?
* Do the different priming solutions affect the total fluid balance in connection with cardiac surgery?
* Do the different priming solutions affect the osmolality in the blood per- and postoperatively?
* Do the different priming solutions affect postoperative renal function? Do the different priming solutions affect neurological outcome?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acid Base Imbalance Osmolality Disturbance Crystalloid Solutions Electrolyte Changes Cardiopulmonary Bypass

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ringer's Acetate 80

Ringer's Acetate 1100 ml with addition of 80 mmol NaCl

Group Type ACTIVE_COMPARATOR

Ringer's Acetate 80

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml and 80 mmol NaCl

Plasmalyte

Plasmalyte 1100 ml, no addition

Group Type ACTIVE_COMPARATOR

Plasmalyte

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary bypass circuit will be primed with Plasmalyte 1100 ml, no addition.

Ringer's Acetate no add

Ringer's Acetate 1100 ml, no addition

Group Type ACTIVE_COMPARATOR

Ringer's Acetate no add

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml no addition

Ringer's Acetate 160

Ringer's Acetate with addition of 160 mmol NaCl

Group Type ACTIVE_COMPARATOR

Ringer's Acetate 160

Intervention Type DIAGNOSTIC_TEST

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml and 160 mmol NaCl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ringer's Acetate 80

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml and 80 mmol NaCl

Intervention Type DIAGNOSTIC_TEST

Plasmalyte

Cardiopulmonary bypass circuit will be primed with Plasmalyte 1100 ml, no addition.

Intervention Type DIAGNOSTIC_TEST

Ringer's Acetate no add

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml no addition

Intervention Type DIAGNOSTIC_TEST

Ringer's Acetate 160

Cardiopulmonary bypass circuit will be primed with Ringer's Acetate 1100 ml and 160 mmol NaCl

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years and above
* Undergoing coronary artery bypass graft (CABG) surgery as single surgery
* Undergoing aortic valve replacement (AVR) as single surgery (AtriClip is allowed)
* Given consent to participate, both verbal and written

Exclusion Criteria

* Subnormal heart function (defined as an ejection fraction \<45%), and no signs of heart failure (edema).
* Body weight \<60 kg or \>120 kg
* Preoperative hemoglobin \<120 g/L,
* Subnormal kidney function (defined as GFR \<30 ml/min),
* Blood sodium outside normal range (135-145 mmol/l),
* Need of acute surgery
* AVR due to aortic valve insufficiency
* Changes in operating method or addition of intraoperative procedures.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Skane

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Snejana Hyllén, Phd,MD

Role: PRINCIPAL_INVESTIGATOR

Region Skane

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skane University hospital

Lund, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Snejana Hyllén, PhD

Role: CONTACT

+46 763131231

References

Explore related publications, articles, or registry entries linked to this study.

Surabhi S, Kumar M. Comparison of ringer's lactate and plasmalyt-a as cardiopulmonary bypass prime for bypass associated acidosis in valve replacement surgeries. Ann Card Anaesth. 2021 Jan-Mar;24(1):36-41. doi: 10.4103/aca.ACA_104_19.

Reference Type BACKGROUND
PMID: 33938829 (View on PubMed)

Ljunggren M, Skold A, Dardashti A, Hyllen S. The use of mannitol in cardiopulmonary bypass prime solution-Prospective randomized double-blind clinical trial. Acta Anaesthesiol Scand. 2019 Nov;63(10):1298-1305. doi: 10.1111/aas.13445. Epub 2019 Jul 29.

Reference Type BACKGROUND
PMID: 31287556 (View on PubMed)

Malmqvist G, Claesson Lingehall H, Appelblad M, Svenmarker S. Cardiopulmonary bypass prime composition: beyond crystalloids versus colloids. Perfusion. 2019 Mar;34(2):130-135. doi: 10.1177/0267659118793249. Epub 2018 Aug 16.

Reference Type BACKGROUND
PMID: 30114960 (View on PubMed)

Wahba A, Kunst G, De Somer F, Agerup Kildahl H, Milne B, Kjellberg G, Bauer A, Beyersdorf F, Berg Ravn H, Debeuckelaere G, Erdoes G, Haumann RG, Gudbjartsson T, Merkle F, Pacini D, Paternoster G, Onorati F, Ranucci M, Ristic N, Vives M, Milojevic M; EACTS/EACTAIC/EBCP Scientific Document Group. 2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg. 2025 Feb 4;67(2):ezae354. doi: 10.1093/ejcts/ezae354. No abstract available.

Reference Type BACKGROUND
PMID: 39949326 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-02925-01-749040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.